Microbiota alterations in patients treated for susceptible or drug-resistant TB
BACKGROUND: We investigated alterations of human microbiota under anti-TB therapies in relationship to the level of Mycobacterium tuberculosis drug response. METHODS: Stool, sputum, and oral swab samples were analysed from participants with treatment-naïve TB and participants treated for drug-suscep...
Saved in:
Main Authors: | M. Hauptmann, B. Kalsdorf, J.E. Akoh-Arrey, C. Lange, U.E. Schaible |
---|---|
Format: | Article |
Language: | English |
Published: |
International Union Against Tuberculosis and Lung Disease (The Union)
2024-08-01
|
Series: | IJTLD Open |
Subjects: | |
Online Access: | https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000008/art00005 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A CLINICAL CASE OF HOSPITAL-ACQUIRED PNEUMONIA CAUSED BY KLEBSIELLA PNEUMONIA, DUE TO CONTACT WITH A FAMILY MEMBER
by: N.D. Gerasymenko, et al.
Published: (2021-12-01) -
Assessment of Haematological Parameters in Drug-Resistant TB
by: Abdulrazzaq Neamah Zghair
Published: (2023-03-01) -
A phase III, randomized, controlled noninferiority trial to study the efficacy and safety of imipenem/cilastatin/relebactam (IMI/REL) vs piperacillin/tazobactam (PIP/TAZ) in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP)
by: Junjie Li, et al.
Published: (2025-04-01) -
Mycobacterium goodii pulmonary disease with organizing pneumonia: A case report and review of literature
by: Yu Shionoya, et al.
Published: (2025-01-01) -
Activity of Aztreonam-avibactam and other β-lactamase inhibitor combinations against Gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2020–2022)
by: Helio S. Sader, et al.
Published: (2025-01-01)